Is this a breakout or just noise?
Feels like a classic late-cycle gamble. With rates still sticky and pharma capex tight, big biotechs are cautious. If reimbursement pressures persist and pipeline timelines slip, any partner deal could get watered down.
Kinda intrigued, but I’m not jumping in. Waiting to see if they actually name a partner or just keep spinning.
Anyone tracking the exact short float and average daily volume for $LLY? How does it compare to last year’s margin-call episodes?
Rates still high, feels like more margin drama.
Everyone’s bracing for a panic, but I think the short squeeze is already priced in. Liquidity’s tight, sure, but $LLY’s cash flow and balance sheet are solid. If rates ease, shorts cover themselves.
Anyone buying dips in $BMNR after this pump?
Feels like the DiP is getting bid by retail; if it holds, momentum traders might keep pushing, but it’s still thin.
I’m kinda new here, but this “DiP” thing sounds like a pump-and-dump bait. I want to learn, but I’m nervous buying into hype without seeing real fundamentals or volume confirmation.
I’m long $LUNC from the start and added today on dips, but I’m watching the DiP chatter closely. If it’s just bots and FOMO, I’ll trim before another headline pop. Otherwise, I’ll ride the volatility.
I’m not convinced this is a durable setup. VIX spikes usually unwind fast, and SOXS has thin liquidity and bid-ask spreads that can punish quick entries. Without improving fundamentals, I’d rather hold cash and wait for a pullback.
Quick trade: buy SOXS on VIX spike, or wait?
Honestly, this feels like classic panic relief. I’m tempted to nibble SOXS while VIX is elevated, but I’m nervous about whipsaws. Might just keep a small position and watch how it behaves over the next few sessions.
